呼吸道融合細胞病毒藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、劑型、治療類型、分銷管道、地區和競爭格局分類，2021-2031年

全球呼吸道融合細胞病毒(RSV) 藥物市場預計將從 2025 年的 20.4 億美元成長到 2031 年的 29.3 億美元，複合年成長率為 6.22%。

該市場涵蓋疫苗、預防性單株抗體以及用於治療或預防下呼吸道感染疾病的治療藥物。推動市場成長的主要因素包括：迫切需要降低嬰幼兒和老年人（感染風險較高）的住院率；以及全球人口老化加劇，亟需強力的預防性醫療保健策略。這些核心促進因素促進了對有效免疫產品的穩定需求，而該行業具有強大的抗市場波動能力。

另一方面，諸如接種疫苗的猶豫不決以及近期核准產品的推廣速度緩慢等因素，是收入成長的主要障礙。對新疫苗的懷疑和公眾認知不足常常阻礙這些生物治療方法的商業性。例如，根據美國國家感染疾病基金會的報告，到2024年，美國60歲及以上成年人的呼吸道融合細胞病毒（RSV）疫苗接種率將僅為24%，凸顯了疫苗廣泛推廣的難度。

市場促進因素

由於近期監管部門的核准和創新疫苗的推出，全球呼吸道合胞病毒（RSV）藥物市場正在經歷根本性的變革。針對老年人的標靶疫苗和針對嬰幼兒的長效單株抗體的推出，為製藥業帶來了新的收入來源。這種從症狀治療轉向預防醫學的趨勢，使企業能夠在病毒爆發高峰期創造顯著價值。賽諾菲在2024年第三季財報中指出，其抗體產品Bayfortus僅在第三季就實現了6.47億歐元的全球銷售額，這充分證明了這一成功。這主要得益於季節性高需求以及該產品迅速被納入免疫通訊協定，也印證了製藥業向預防性生物製藥領域轉型的合理性。

呼吸道合胞病毒（RSV）相關住院治療帶來的沉重負擔是推動相關疫苗上市的關鍵因素，因為醫療系統正努力控制與嚴重呼吸系統疾病相關的成本。降低新生兒和老年人等高風險族群住院率的迫切臨床需求正在推動這些新療法的應用。美國疾病管制與預防中心（CDC）在2024年6月的報告中指出，RSV每年導致美國60歲及以上成年人約10萬至16萬人住院，凸顯了龐大的病患族群亟需治療。滿足此需求的經濟規模顯而易見，葛蘭素史克（GSK）在2023年全年財報中公佈，其Alexby疫苗的總銷售額達到12億英鎊。

市場挑戰

全球呼吸道合胞病毒（RSV）藥物市場的商業性擴張主要受疫苗接種意願低迷和新核准產品推廣緩慢的限制。儘管新的預防和治療方案不斷湧現，但普遍存在的懷疑態度和公眾認知不足嚴重限制了可接受治療的患者群體。這種對生物製藥推廣的抵制導致研發公司銷售量下降，投資回報延遲，因為理論市場規模無法轉化為預期的實際收入。因此，企業面臨庫存積壓的困境，並被迫進行高成本、耗時漫長的宣傳宣傳活動，而這些活動無法即時產生經濟效益。

這種市場滲透率低的問題在最需要預防的人群中尤其明顯。例如，根據美國疾病管制與預防中心（CDC）的數據，到2024年，2023-2024年度孕婦的呼吸道合胞病毒（RSV）疫苗接種率僅為32.6%。如此低的疫苗接種率清楚地表明，猶豫不決和延遲接種會如何阻礙市場成長。因此，該產業正面臨成長停滯，先進治療方法的經濟潛力也因難以獲得終端用戶的認可而受到限制。

市場趨勢

在這一領域，隨著mRNA技術平台在新型呼吸道合胞病毒（RSV）疫苗研發中的應用日益廣泛，一場革命性的變革正在發生。這使得高效疫苗的快速研發成為可能。這項技術進步超越了傳統的蛋白質次單元技術，實現了可擴展的生產規模和針對融合前F蛋白的精準抗原設計。第一款以mRNA為基礎的RSV疫苗的核准，充分展現了這項創新，並為未來的生物製藥樹立了新的標竿。 2024年5月，Moderna公司發布新聞稿宣布，其mRESVIA疫苗已獲得美國FDA核准，該疫苗在60歲及以上成年人對RSV引起的下呼吸道疾病的有效率達到83.7%。

此外，小分子口服抗病毒療法的臨床開發平臺進展標誌著治療策略從傳統的預防為主轉向急性疾病管理。製藥公司正在開發口服療法，以幫助感染患者，並專注於疫苗接種後的感染病例和未接種疫苗的高風險族群。這些創新治療方法旨在透過顯著抑制病毒複製來減輕症狀嚴重程度並阻止病毒傳播。 Enanta Pharmaceuticals公司就是這項進展的典型例證。該公司於2024年9月公佈了其IIa期人體挑戰試驗的主要結果。與安慰劑相比，該公司的口服抗病毒候選藥物EDP-323使病毒量曲線下面積降低了85%至87%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：呼吸道融合細胞病毒的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類型（帕利珠單抗、Ribavirin、其他）
  • 劑型（口服、注射、其他）
  • 治療類型（抗病毒藥物、免疫抑制劑、其他）
  • 分銷管道（醫院藥房、專科藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美呼吸道融合細胞病毒（RSV）藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲呼吸道融合細胞病毒（RSV）藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區呼吸道融合細胞病毒（RSV）藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲呼吸道融合細胞病毒（RSV）藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美呼吸道融合細胞病毒（RSV）藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球呼吸道融合細胞病毒（RSV）藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AbbVie, Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck KgaA
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Respiratory Syncytial Virus (RSV) Drugs Market is projected to expand from USD 2.04 Billion in 2025 to USD 2.93 Billion by 2031, reflecting a compound annual growth rate of 6.22%. This market encompasses vaccines, prophylactic monoclonal antibodies, and therapeutic agents designed to treat or prevent lower respiratory tract infections. Growth is primarily propelled by the urgent necessity to lower hospitalization rates in susceptible infants and seniors, along with the worldwide increase in the aging population that necessitates strong preventive health strategies. These core drivers foster a consistent demand for effective immunizations, distinguishing this sector from transient market fluctuations.

Conversely, the market encounters substantial obstacles related to vaccine hesitancy and the sluggish uptake of recently authorized products, factors that jeopardize revenue growth. Skepticism surrounding new immunizations and insufficient public awareness frequently constrain the commercial reach of these biological treatments. For instance, the National Foundation for Infectious Diseases reported that in 2024, vaccination rates for respiratory syncytial virus among adults aged 60 and older in the United States stood at merely 24%, highlighting the difficulties in achieving widespread adoption.

Market Driver

The Global RSV Drugs Market is being fundamentally transformed by recent regulatory clearances and the rollout of innovative vaccines. The introduction of targeted immunizations for seniors and long-acting monoclonal antibodies for infants has created a new financial foundation for the pharmaceutical industry. This transition from treating symptoms to preventative care enables companies to generate substantial value during peak viral seasons. As evidence of this success, Sanofi reported in its Q3 2024 results that global sales for the antibody Beyfortus hit €647 million in the third quarter alone, driven by robust seasonal demand and quick integration into immunization protocols, validating the industry's pivot toward preventative biologics.

The significant burden of RSV-related hospital admissions serves as a crucial catalyst for market adoption, as healthcare systems strive to control costs linked to severe respiratory illness. The pressing clinical requirement to decrease admission rates among high-risk groups, such as neonates and the elderly, drives the utilization of these new therapeutics. The Centers for Disease Control and Prevention noted in a June 2024 report that RSV causes roughly 100,000 to 160,000 annual hospitalizations among US adults over 60, highlighting the vast patient population needing care. The economic magnitude of meeting this need is clear, with GSK reporting £1.2 billion in total sales for its Arexvy vaccine in its full-year 2023 results.

Market Challenge

Commercial expansion of the Global RSV Drugs Market is significantly hindered by vaccine hesitancy and the slow uptake of newly approved products. Although novel prophylactic and therapeutic options have been introduced, widespread skepticism and a lack of public knowledge severely limit the accessible patient population. This resistance to adopting biological agents results in lower sales volumes and a delayed return on investment for developers, as the theoretical market size does not translate into actual revenue as anticipated. Consequently, companies face the issue of unmoving inventory and the need for expensive, prolonged educational campaigns that fail to deliver immediate financial benefits.

This pattern of weak market penetration is particularly noticeable in demographic segments where protection is most needed. For example, data from the Centers for Disease Control and Prevention indicated that maternal RSV vaccination coverage for the 2023-2024 season was only 32.6% in 2024. Such depressed immunization rates among priority groups clearly illustrate how hesitancy and sluggish adoption curb market growth. As a result, the industry confronts a flattened growth curve where the economic promise of advanced therapies is stifled by the enduring difficulty of securing end-user acceptance.

Market Trends

The sector is being revolutionized by the adoption of mRNA technology platforms for formulating novel RSV vaccines, facilitating the swift creation of highly effective immunizations. This technological advancement surpasses conventional protein subunit techniques by allowing for scalable manufacturing and precise antigen design targeting the prefusion F protein. The approval of the first mRNA-based RSV vaccine served as a validation of this innovation, setting a new standard for future biologics. In a May 2024 press release, Moderna announced that its mRESVIA vaccine received US FDA approval after demonstrating an efficacy of 83.7% against lower respiratory tract disease caused by RSV in adults aged 60 and older.

Furthermore, the advancement of small molecule oral antiviral therapeutics in clinical pipelines marks a significant shift from strictly prophylactic approaches to acute disease management. Pharmaceutical companies are developing oral treatments to help infected patients, specifically addressing cases of vaccine breakthrough or high-risk individuals who remain unvaccinated. These innovative therapies are designed to drastically lower viral replication, thereby reducing symptom severity and halting transmission. Highlighting this progress, Enanta Pharmaceuticals reported positive topline results in September 2024 from a Phase 2a human challenge study, where their oral antiviral candidate EDP-323 achieved an 85% to 87% reduction in viral load area under the curve compared to a placebo.

Key Market Players

• AbbVie, Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck KgaA
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.

Report Scope

In this report, the Global Respiratory Syncytial Virus (RSV) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Syncytial Virus (RSV) Drugs Market, By Drug Type

• Palivizumab
• Ribavirin
• Others

Respiratory Syncytial Virus (RSV) Drugs Market, By Dosage Form

• Oral
• Injectable
• Others

Respiratory Syncytial Virus (RSV) Drugs Market, By Treatment Type

• Antiviral Medications
• Immune prophylaxis
• Others

Respiratory Syncytial Virus (RSV) Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Respiratory Syncytial Virus (RSV) Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Syncytial Virus (RSV) Drugs Market.

Available Customizations:

Global Respiratory Syncytial Virus (RSV) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Palivizumab, Ribavirin, Others)
  • 5.2.2. By Dosage Form (Oral, Injectable, Others)
  • 5.2.3. By Treatment Type (Antiviral Medications, Immune prophylaxis, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Dosage Form
  • 6.2.3. By Treatment Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Dosage Form
      • 6.3.1.2.3. By Treatment Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Dosage Form
      • 6.3.2.2.3. By Treatment Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Dosage Form
      • 6.3.3.2.3. By Treatment Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Dosage Form
  • 7.2.3. By Treatment Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Dosage Form
      • 7.3.1.2.3. By Treatment Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Dosage Form
      • 7.3.2.2.3. By Treatment Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Dosage Form
      • 7.3.3.2.3. By Treatment Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Dosage Form
      • 7.3.4.2.3. By Treatment Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Dosage Form
      • 7.3.5.2.3. By Treatment Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Dosage Form
  • 8.2.3. By Treatment Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Dosage Form
      • 8.3.1.2.3. By Treatment Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Dosage Form
      • 8.3.2.2.3. By Treatment Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Dosage Form
      • 8.3.3.2.3. By Treatment Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Dosage Form
      • 8.3.4.2.3. By Treatment Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Dosage Form
      • 8.3.5.2.3. By Treatment Type
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Dosage Form
  • 9.2.3. By Treatment Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Dosage Form
      • 9.3.1.2.3. By Treatment Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Dosage Form
      • 9.3.2.2.3. By Treatment Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Dosage Form
      • 9.3.3.2.3. By Treatment Type
      • 9.3.3.2.4. By Distribution Channel

10. South America Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Dosage Form
  • 10.2.3. By Treatment Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Dosage Form
      • 10.3.1.2.3. By Treatment Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Dosage Form
      • 10.3.2.2.3. By Treatment Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Dosage Form
      • 10.3.3.2.3. By Treatment Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Respiratory Syncytial Virus (RSV) Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca PLC
• 15.3. Bausch Health Companies Inc.
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Gilead Sciences, Inc.
• 15.6. GlaxoSmithKline PLC
• 15.7. Merck KgaA
• 15.8. Pfizer Inc.
• 15.9. Teva Pharmaceutical Industries Ltd.
• 15.10. Johnson & Johnson Services, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer